CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 70 enrolled
Drug / intervention
400 ug Brimonidine Implant +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00693485
NCT00693485Phase 2Completed
CompareCT.gov

Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy

Allergan·interventional·Posted Jun 9, 2008·Updated Apr 24, 2013

In Brief

A Phase 2 clinical trial evaluating 400 ug Brimonidine Implant, 200 ug Brimonidine Implant, and 1 other intervention for Glaucoma, Open-Angle. Completed, enrolled 70 participants across 2 sites in 2 countries.

Detailed Summary

A multicenter, randomized, patient-masked, sham-controlled evaluation of the safety and effects on visual function of brimonidine intravitreal implant in patients with glaucomatous optic neuropathy. Patients will be followed for up to 1 year.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Open-Angle
CountriesIsrael, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 9, 2008
Enrollment StartSep 1, 2008
Primary CompletionJan 1, 2011
Study CompletionAug 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 18.1 years ago

Interventions

400 ug Brimonidine Implantdrug

400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.

200 ug Brimonidine Implantdrug

200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.

Sham (no implant)drug

Sham Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.